REPL
Replimune Group, Inc.
Nasdaq · usd
Replimune Group, Inc. (REPL) trades at $19.72 (+0.13%) as of 6:21:42 AM EST on Nov 19, 2026, +73.47% over the past month. Market cap is $1.88B, with 8.3 days to cover in short interest.
Stock performance
How Replimune Group, Inc. (REPL) stock has performed from one day to one year, with its 52-week range.
- 1D
- +0.61%
- 1W
- -9.04%
- 1M
- +73.47%
- YTD
- +103.81%
- 1Y
- +119.87%
- 52-wk range
- $1.50 – $23.54
Key statistics
Today's trading snapshot for REPL: day range, open, previous close, volume and market cap.
- Day range
- $19.33 – $20.12
- Open
- $19.63
- Prev close
- $19.69
- Volume
- 2.13M
- Market cap
- $1.88B
- Shares out
- 94.8M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Replimune Group, Inc.: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- —
- P/B
- 9.17
- P/FCF
- —
- ROE
- -132.4%
- ROA
- -72.5%
- Debt/Equity
- 0.61
- Div yield
- 0.00%
As of Nov 18, 2026
8-K filings
Material corporate events Replimune Group, Inc. has disclosed to the SEC on Form 8-K.
- Quarterly earningsOct 28, 2026
On October 28, 2026, Replimune Group, Inc. issued a news release announcing its financial results for the second fiscal quarter ended September 30, 2026 and certain corporate updates.
- Annual meeting resultsSep 16, 2026
The final voting results on each of the matters submitted to a vote of stockholders at the Annual Meeting are set forth below. ... Proposal No. 1 ... was ratified; Proposal No. 2 ... was approved on a non-binding advisory basis; [and] Proposal No. 3 ... was approved by the Company's stockholders.
- Public offeringAug 10, 2026
On August 9, 2026, Replimune Group, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Leerink Partners LLC, J.P. Morgan Securities LLC, and Cantor Fitzgerald & Co. relating to the issuance and sale of an aggregate of 9,701,490 shares of the Company's common stock (the "Shares") and pre-funded warrants to purchase 2,736,340 shares of the Company's common stock (the "Pre-Funded Warrants"). The Shares will be sold at the offering price of $12.06 per share and the Pre-Funded Warrants will be sold at an offering price of $12.0599 per Pre-Funded Warrant.
- Regulatory decisionAug 7, 2026
the U.S. Food and Drug Administration has granted accelerated approval for TUDRIQEVTM (vusolimogene oderparepvec-wtpg), previously referred to as RP1, in combination with nivolumab for the treatment of adults with unresectable advanced cutaneous melanoma who experienced disease progression on an anti-PD-1 antibody-based regimen.
- Regulatory decisionJul 31, 2026
The U.S. Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee met to discuss the Company's Biologics License Application ("BLA") resubmission for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. The Advisory Committee voted 10 to 3 that the efficacy results from the IGNYTE study are evaluable and clinically meaningful.
Dividend history and stock splits
Replimune Group, Inc.'s recent dividend payments and stock splits.
Dividends
No recent dividends.
Splits
- 15-for-1Dec 1, 2010
REPL short interest
How heavily REPL is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 8.3
- Short interest
- 24.61M
- Avg volume
- 2.96M
As of · reported to FINRA twice monthly.
REPL news
The latest news and headlines about Replimune Group, Inc. (REPL).
- Wall Street Analysts Think Replimune Group (REPL) Could Surge 29.51%: Read This Before Placing a BetpositiveZacks Investment Research· Nov 18, 2026
- REPL Stock Up 80% in a Month on Tudriqev Launch & Pipeline ProgresspositiveZacks Investment Research· Nov 12, 2026
- Wall Street Analysts Believe Replimune Group (REPL) Could Rally 26.8%: Here's is How to TradepositiveZacks Investment Research· Nov 2, 2026
- Replimune: 3 Key Takeaways for Long-Term InvestorspositiveThe Motley Fool· Oct 28, 2026
- Mestag Therapeutics Appoints Philip Astley-Sparke and Victor Sandor, M.D.C.M., to its Board of DirectorspositiveGlobeNewswire Inc.· Oct 20, 2026
Frequently asked questions
What is the Replimune Group, Inc. (REPL) stock price today?
Replimune Group, Inc. (REPL) is trading at $19.72 (+0.13% on the day) as of 6:21:42 AM EST on Nov 19, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Replimune Group, Inc.?
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies.
What is the short interest in REPL?
As of Oct 30, 2026, REPL has 24.61M shares short and 8.3 days to cover.
What exchange is REPL listed on?
Replimune Group, Inc. (REPL) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.
Build with AI
Build an analysis of REPL with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a REPL analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.